Peptide-based imaging agent developer Diatide has announced that it has received an approvable letter from the Food and Drug Administration for its AcuTect technetium-labeled agent for the imaging of acute venous thrombosis in the lower extremities. The
Peptide-based imaging agent developer Diatide has announced that it has received an approvable letter from the Food and Drug Administration for its AcuTect technetium-labeled agent for the imaging of acute venous thrombosis in the lower extremities. The letter arrived exactly six months following the submission of the new drug application (NDA) to the FDA (SCAN 9/3/97).
The letter indicates that Diatide's NDA will be approved once the company clarifies certain details and formally agrees to specific postapproval requirements, according to the Londonderry, NH-based firm. Diatide expects to begin to co-market AcuTect in the U.S. with its corporate partner Nycomed Amersham immediately following approval of the agent.
Could Virtual Non-Contrast Images from Photon-Counting CT Reduce Radiation Dosing with CCTA?
March 28th 2024Emerging research on coronary artery calcium scoring for the assessment of coronary artery disease (CAD) suggests the use of virtual non-contrast images from photon-counting CT may lead to a nearly 20 percent reduction in radiation dosing.
FDA Clears CT-Based AI Tools for PE Detection and Stroke Severity Assessment
March 26th 2024The artificial intelligence (AI) modalities CINA-iPE and CINA-ASPECTS may facilitate improved detection of incidental pulmonary embolism and stroke evaluation, respectively, based on computed tomography (CT) scans.